Six-year PERSEUS results show 81% of newly diagnosed, transplant-eligible myeloma patients had no cancer progression, with many stopping Darzalex.
|Videos|January 5, 2017
MM4MM 2017 Kilimanjaro Team Training Climb
This year, a group of patients, advocates and health care professionals will tackle Mount Kilimanjaro to raise money and awareness for multiple myeloma.
Advertisement
This year, a group of patients, advocates and health care professionals will tackle Mount Kilimanjaro to raise money and awareness for multiple myeloma.
For more information, visit MMforMM.com.
Advertisement
Related to this article
A leukemia survivor recalls how bonding with other patients helped his hospital stays go by faster and became a key part of his emotional healing.
Ivonescimab outperformed Keytruda, a new myeloma drug lowered progression risk by 60% and more: the biggest phase 3 cancer results of September 2026.
Learn how to cope with life after cancer treatment with Dr. Eric Bengtsen, a psycho-oncology psychiatrist at Memorial Sloan Kettering Cancer Center.
Six years after being diagnosed with B-cell ALL at 21, William Yank opens up about the physical changes of treatment, the emotional weight of constant care and the role hope plays in his survivorship.
Advertisement
Advertisement
Trending on CURE
1
FDA Approves Tukysa Combination as Maintenance for HER2-Positive Breast Cancer
2
Exercise Gave Me Control. It Didn’t Cure My Cancer
3
Living With Incurable Cancer: The Emotional Toll of Never Knowing What Comes Next
4
Early Depression Treatment May Be Linked to Lower Cancer Death Risk
5